Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOAC-FRAIL RCT
2025-521362-10-00Phase 4Authorised
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of apixaban, dabigatran, rivaroxaban and edoxaban in Atrial fibrillation (AFib) and venous thromboembolism (VTE) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Composite outcome of thromboembolic events or bleedings. Planned start Jul 2025; status: authorised.
02
Drugs
apixabandabigatranrivaroxabanedoxaban
03
Conditions
Atrial fibrillation (AFib)venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2025-521362-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521362-10-00.